OBJECTIVE: The aim of the study was to compare time-trends in mortality rates and treatment patterns between patients with and without diabetes based on the Swedish register of coronary care (Register of Information and Knowledge about Swedish Heart Intensive Care Admission [RIKS-HIA]). METHODS: Post myocardial infarction mortality rate is high in diabetic patients, who seem to receive less evidence-based treatment. Mortality rates and treatment in 1995-1998 and 1999-2002 were studied in 70,882 patients (age <80 years), 14 873 of whom had diabetes (the first registry recorded acute myocardial infarction), following adjustments for differences in clinical and other parameters. RESULTS: One-year mortality rates decreased from 1995 to 2002 from 16.6% to 12.1% in patients without diabetes and from 29.7% to 19.7%, respectively, in those with diabetes. Patients with diabetes had an adjusted relative 1-year mortality risk of 1.44 (95% CI 1.36 to 1.52) in 1995-1998 and 1.31 (95% CI 1.24 to 1.38) in 1999-2002. Despite improved pre-admission and in-hospital treatment, diabetic patients were less often offered acute reperfusion therapy (adjusted OR 0.85, 95% CI 0.80 to 0.90), acute revascularisation (adjusted OR 0.78, 95% CI 0.69 to 0.87) or revascularisation within 14 days (OR 0.80, 95% CI 0.75 to 0.85), aspirin (OR 0.90, 95% CI 0.84 to 0.98) and lipid-lowering treatment at discharge (OR 0.81, 95% CI 0.77 to 0.86). CONCLUSION: Despite a clear improvement in the treatment and myocardial infarction survival rate in patients with diabetes, mortality rate remains higher than in patients without diabetes. Part of the excess mortality may be explained by co-morbidities and diabetes itself, but a lack of application of evidence-based treatment also contributes, underlining the importance of the improved management of diabetic patients.
OBJECTIVE: The aim of the study was to compare time-trends in mortality rates and treatment patterns between patients with and without diabetes based on the Swedish register of coronary care (Register of Information and Knowledge about Swedish Heart Intensive Care Admission [RIKS-HIA]). METHODS: Post myocardial infarction mortality rate is high in diabeticpatients, who seem to receive less evidence-based treatment. Mortality rates and treatment in 1995-1998 and 1999-2002 were studied in 70,882 patients (age <80 years), 14 873 of whom had diabetes (the first registry recorded acute myocardial infarction), following adjustments for differences in clinical and other parameters. RESULTS: One-year mortality rates decreased from 1995 to 2002 from 16.6% to 12.1% in patients without diabetes and from 29.7% to 19.7%, respectively, in those with diabetes. Patients with diabetes had an adjusted relative 1-year mortality risk of 1.44 (95% CI 1.36 to 1.52) in 1995-1998 and 1.31 (95% CI 1.24 to 1.38) in 1999-2002. Despite improved pre-admission and in-hospital treatment, diabeticpatients were less often offered acute reperfusion therapy (adjusted OR 0.85, 95% CI 0.80 to 0.90), acute revascularisation (adjusted OR 0.78, 95% CI 0.69 to 0.87) or revascularisation within 14 days (OR 0.80, 95% CI 0.75 to 0.85), aspirin (OR 0.90, 95% CI 0.84 to 0.98) and lipid-lowering treatment at discharge (OR 0.81, 95% CI 0.77 to 0.86). CONCLUSION: Despite a clear improvement in the treatment and myocardial infarction survival rate in patients with diabetes, mortality rate remains higher than in patients without diabetes. Part of the excess mortality may be explained by co-morbidities and diabetes itself, but a lack of application of evidence-based treatment also contributes, underlining the importance of the improved management of diabeticpatients.
Authors: Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: Michel E Bertrand; Maarten L Simoons; Keith A A Fox; Lars C Wallentin; Christian W Hamm; Eugene McFadden; Pim J De Feyter; Giuseppe Specchia; Witold Ruzyllo Journal: Eur Heart J Date: 2002-12 Impact factor: 29.983
Authors: D K McGuire; H Emanuelsson; C B Granger; E Magnus Ohman; D J Moliterno; H D White; D Ardissino; J W Box; R M Califf; E J Topol Journal: Eur Heart J Date: 2000-11 Impact factor: 29.983
Authors: I Gustafsson; P Hildebrandt; M Seibaek; T Melchior; C Torp-Pedersen; L Køber; P Kaiser-Nielsen Journal: Eur Heart J Date: 2000-12 Impact factor: 29.983
Authors: K Malmberg; S Yusuf; H C Gerstein; J Brown; F Zhao; D Hunt; L Piegas; J Calvin; M Keltai; A Budaj Journal: Circulation Date: 2000-08-29 Impact factor: 29.690
Authors: K Malmberg; L Rydén; S Efendic; J Herlitz; P Nicol; A Waldenström; H Wedel; L Welin Journal: J Am Coll Cardiol Date: 1995-07 Impact factor: 24.094
Authors: Tong Lu; Qiang Chai; Guoqing Jiao; Xiao-Li Wang; Xiaojing Sun; Jonathan D Furuseth; John M Stulak; Richard C Daly; Kevin L Greason; Yong-Mei Cha; Hon-Chi Lee Journal: Cardiovasc Res Date: 2019-01-01 Impact factor: 10.787
Authors: Yajing Wang; Erhe Gao; Ling Tao; Wayne Bond Lau; Yuexin Yuan; Barry J Goldstein; Bernard L Lopez; Theodore A Christopher; Rong Tian; Walter Koch; Xin-Liang Ma Journal: Circulation Date: 2009-02-02 Impact factor: 29.690
Authors: Adam N Mather; Andrew Crean; Nik Abidin; Gillian Worthy; Stephen G Ball; Sven Plein; John P Greenwood Journal: J Cardiovasc Magn Reson Date: 2010-11-02 Impact factor: 5.364